RILZOVA Trademark

Trademark Overview

On Friday, January 8, 2021, a trademark application was filed for RILZOVA with the United States Patent and Trademark Office. The USPTO has given the RILZOVA trademark a serial number of 79306200. The federal status of this trademark filing is REGISTERED as of Tuesday, March 21, 2023. This trademark is owned by Glaxo Group Limited. The RILZOVA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines
rilzova

General Information

Serial Number79306200
Word MarkRILZOVA
Filing DateFriday, January 8, 2021
Status700 - REGISTERED
Status DateTuesday, March 21, 2023
Registration Number7002473
Registration DateTuesday, March 21, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 3, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 12, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type77 - NOT AVAILABLE
AddressGB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type77 - NOT AVAILABLE
AddressGB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type77 - NOT AVAILABLE
AddressGB

Trademark Events

Event DateEvent Description
Friday, August 11, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Friday, July 21, 2023FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, June 26, 2023FINAL DISPOSITION NOTICE SENT TO IB
Monday, June 26, 2023FINAL DISPOSITION PROCESSED
Wednesday, June 21, 2023FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, March 21, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, March 21, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, January 3, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 3, 2023PUBLISHED FOR OPPOSITION
Wednesday, December 14, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, November 28, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Sunday, September 4, 2022NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, August 17, 2022NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, August 17, 2022NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Monday, August 15, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, July 22, 2022SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Tuesday, January 18, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, January 18, 2022LETTER OF SUSPENSION E-MAILED
Tuesday, January 18, 2022SUSPENSION LETTER WRITTEN
Saturday, January 15, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 14, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 14, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, August 15, 2021REFUSAL PROCESSED BY IB
Wednesday, July 28, 2021NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, July 28, 2021REFUSAL PROCESSED BY MPU
Wednesday, July 21, 2021NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, July 20, 2021NON-FINAL ACTION WRITTEN
Monday, July 19, 2021ASSIGNED TO EXAMINER
Tuesday, March 16, 2021APPLICATION FILING RECEIPT MAILED
Friday, March 12, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 12, 2021LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, March 11, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

rilzova pharmaceutical treatment disorders preparations substances diseases ophthalmic respiratory hepatological oncological